Healthcare Industry News: cataract
News Release - August 3, 2009
Bausch & Lomb Surgical Launches the Akreos(R) AO Micro Incision IOLROCHESTER, N.Y., Aug. 3 -- (Healthcare Sales & Marketing Network) -- Bausch & Lomb Surgical has announced the US launch of its new AkreosŪ AO Micro Incision Lens (Model MI60L). In the US, the company refers to this lens as the AkreosŪ MICS(TM) lens. This unique spherical aberration free lens has been specifically developed for 1.8 mm MICS(TM). Its award winning design and glistening free material allows implantation through a 1.8 mm incision, while maintaining the optical quality and stability first established with the parent Akreos AO lens design. Akreos lenses have a history of over ten years since the first implant in Europe and to date there have been more than 3 million Akreos lenses implanted worldwide.
When the AkreosŪ MICS(TM) lens is coupled with the Stellaris MICS(TM) Vision Enhancement System, small incision surgeons can now enjoy the universal advantages provided by the MICS(TM) Platform. The advantages include increased wound sealability(1), and a reduction in both endothelial cell loss(2) and surgically-induced astigmatism(3).
Dr. John Hunkeler, Overland Park, Kansas City, was chosen to be among the first surgeons to implant the lens in the US. "This is what we've been waiting for. . . a crystal-clear acrylic lens with no yellow tint, vacuoles, or glistenings. I am yet to have any patient complain of edge glare or temporal darkness syndrome that has been reported with other acrylic IOLs. The four-point-fixation offers unparalleled centration. Besides all that, it delivers through a 1.8-mm incision. This is the perfect lens that my patients deserve," said Dr. Hunkeler.
On June 24, 2009 the Centers for Medicare and Medicaid Services ("CMS") granted New Technology Intraocular Lens ("NTIOL") designation to the AkreosŪ MICS(TM) IOL for its spherical aberration reducing design. The NTIOL designation became effective April 30, 2009. NTIOL designation means the Medicare reimbursement to ambulatory surgery centers for cataract surgery will increase by $50 when surgery is performed with the AkreosŪ MICS(TM) IOL.
Mike Judy, vice president of worldwide marketing for Bausch & Lomb Surgical stated, "We have strategically timed the launch of the AkreosŪ MICS(TM) IOL in order to best support surgeons and their patients by providing our latest technological advancements in aspheric optics with NTIOL designation. By introducing an advanced technology lens with a designation that recognizes the high level of performance this lens provides, we continue the Bausch & Lomb tradition of delivering quality products and innovation that perfect vision and enhance life."
Further details on the complete MICS(TM) platform, are available on www.Bauschsurgical.com/MICS.
1. Barrett, G and Carlsson, A. cataract Surgical Wound Strength In Vivo. COS annual meeting and exhibition, 2007, Montreal, Canada.
2. Zafirakis, P. Microincision cataract Surgery. Stellaris Phaco Platform Versus Infiniti Torsional Ultrasound Phaco Mode : Randomized Comparative Clinical Study. ASCRS Symposium on cataract, IOL and Refractive Surgery, 2009, San Francisco, CA.
3. Heg Wee Jin. Surgically Induced Astigmatism in Standard versus Micro Incision Phacoemulsification, WOC 2008, Hong Kong.
About Bausch & Lomb
Bausch & Lomb is dedicated to bringing visionary ideas to eye health. Its core businesses include contact lenses and lens care products, ophthalmic surgical devices and instruments, and ophthalmic pharmaceuticals. The Bausch & Lomb name is one of the best-known and most respected healthcare brands in the world. Founded in 1853, the company is headquartered in Rochester, N.Y., and employs more than 10,000 people worldwide. Its products are available in more than 100 countries. More information is available at www.bausch.com.
Source: Bausch & Lomb
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.